Dominant negative ATM mutations in breast cancer families

Journal of the National Cancer Institute

Volumn 94, Issue 3, 2002, Pages 205-215

  Chenevix Trench, Georgia ^a   Spurdle, Amanda B ^a   Gatei, Magtouf ^a   Kelly, Helena ^a   Marsh, Anna ^a   Chen, Xiaoqing ^a   Donn, Karen ^a   Cummings, Margaret ^b   Nyholt, Dale ^a   Jenkins, Mark A ^c   Scott, Clare ^d   Pupo, Gulietta M ^e   Dörk, Thilo ^f   Bendix, Regina ^f   Kirk, Judy ^g   Tucker, Katherine ^h   McCredie, Margaret R E ^i,j   Hopper, John L ^c   Sambrook, Joseph ^d   Mann, Graham J ^e   Khanna, Kum Kum ^a   more..

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g WESTMEAD HOSPITAL   (Australia)

^h PRINCE OF WALES HOSPITAL   (Australia)

ⁱ CANCER RESEARCH DIVISION   (Australia)

^j UNIVERSITY OF OTAGO   (New Zealand)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; PROTEIN KINASE;

ADULT; ARTICLE; ATAXIA TELANGIECTASIA; AUTOSOMAL RECESSIVE DISORDER; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FAMILY HISTORY; GENE ACTIVITY; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENOTYPE; HETEROZYGOTE; HUMAN; LINKAGE ANALYSIS; LYMPHOBLASTOID CELL LINE; MAJOR CLINICAL STUDY; NEWBORN; PENETRANCE; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 0037028740     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.3.205     Document Type: Article

References (50)

1. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families
2. Incidence of cancer in 161 families affected by ataxia-telangiectasia
3. Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: Haplotype study in French AT families
4. Risk of breast cancer and other cancers in heterozygotes for ataxia- telangiectasia
5. Cancer in patients with ataxia-telangiectasia and in their relatives in the Nordic countries
6. Cancer risk in heterozygotes for ataxia-telangiectasia
7. Cancer risks in A-T heterozygotes
8. Linkage analysis of DRD2, a marker linked to the ataxia-telangiectasia gene, in 64 families with premenopausal bilateral breast cancer
9. Absence of linkage to the ataxia telangiectasia locus in familial breast cancer
10. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer
11. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: Expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer
12. The ATM gene and susceptibility to breast cancer: Analysis of 38 breast tumors reveals no evidence for mutation
13. Heterozygous ATM mutations do not contribute to early onset of breast cancer
14. AT-tributable risks?
15. The role of ataxia-telangiectasia heterozygotes in familial breast cancer
16. Heterozygosity for mutations in the ataxia telangiectasia gene is not a major cause of radiotherapy complications in breast cancer patients
17. Absence of mutations in the ATM gene in breast cancer patients with severe responses to radiotherapy
18. Testing for mutations of the ataxia telangiectasia gene in radiosensitive breast cancer patients
19. Increased risk of breast cancer following irradiation for Hodgkin's disease is not a result of ATM germline mutations
20. Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients
21. DNA double-strand breaks: Signaling, repair and the cancer connection
22. Requirement of ATM-dependent phosphorylation of brcal in the DNA damage response to double-strand breaks
23. Role for ATM in DNA damage-induced phosphorylation of BRCA1
24. Ataxia telangiectasia (ATM) kinase and ATM and Rad3 related kinase mediate phosphorylation of Brca1 at distinct and overlapping sites In vivo assessment using phospho-specific antibodies
25. Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress
26. Frequent splicing mutation of the ATM gene in breast cancer
27. Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer
28. Splicing defects in the ataxia-telangiectasia gene. ATM: Underlying mutations and consequences
29. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility
30. Background, rationale and protocol for a case-control-family study of breast cancer
31. Design and analysis issues in a population-based, case-control-family study of the genetic epidemiology of breast cancer and the Cooperative Family Registry for Breast Cancer Studies (CFRBCS)
32. kConFab: A research resource of Australasian breast cancer families
33. A simple salting out procedure for extracting DNA from human nucleated cells
34. Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique
35. CYP17 promotor polymorphism and ovarian cancer risk
36. BRCA1-related breast cancer in Austrian breast and ovarian cancer families: Specific BRCA1 mutations and pathological characteristics
37. Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in sporadic tumors
38. ATM associates with and phosphorylates p53: Mapping the region of interaction
39. Activation of ATM kinase by ionizing radiation and phosphorylation of p53
40. Faster linkage analysis computations for pedigrees with loops or unused alleles
41. Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families
42. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study
43. Missense mutations in disease genes: A Bayesian approach to evaluate causality
44. Enhanced phosphorylation of p53 by ATM in response to DNA damage
45. Breast and other cancers in families with ataxia-telangiectasia
46. Fragments of ATM which have dominant-negative or complementing activity
47. ATM mutations in cancer families
48. Neoplastic transformation of neonatal human fibroblasts exposed in vitro to radiation from a quartz-halogen lamp
49. Cancer risk in ATM heterozygotes: A model of phenotypic and mechanistic differences between missense and truncating mutations